More on CRBP
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.48 |
|
|||
| Open | $7.51 | ||||
| 52 Wk High | $10.78 | ||||
| 52 Wk Low | $1.01 | ||||
| Day High | $7.79 | ||||
| Day Low | $7.42 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 499,820 | ||||
- Form 4 Corbus Pharmaceuticals For: Sep 14 Filed by: Ben Yong
- H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)
- Form 8-K Corbus Pharmaceuticals For: Sep 14
- Corbus obesity drug hits 5% weight loss mark in phase 1b trial
- Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
- Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
- H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)
- Form 4 Corbus Pharmaceuticals For: Aug 16 Filed by: Nicacio Leonardo Viana
- Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Form SCHEDULE 13G/A Corbus Pharmaceuticals Filed by: CITADEL ADVISORS LLC
Entities mentioned with CRBP
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
